1-5 of 5
Michael Spector
Close
Sort by
Journal Articles

Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1-Year Results from an Open-Label Phase 2 Trial

Jason Valent, Jeffrey A. Zonder, Michaela Liedtke, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Jessica Raviwong, Michael Spector, Susan B. Sobolov
Journal: Blood
Blood (2021) 138 (Supplement 1): 468.
https://doi.org/10.1182/blood-2021-153636
Published: 2021
Journal Articles

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Jason Valent, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Sherry Fada, Michael Spector, Kathleen Stefunek, Heather Staley, Kristen Schlueter, Christy J. Samaras, Faiz Anwer, Jack Khouri, Jeffrey A. Zonder, Michaela Liedtke, Susan B. Sobolov
Journal: Blood
Blood (2021) 138 (Supplement 1): 2724.
https://doi.org/10.1182/blood-2021-148905
Published: 2021
Journal Articles

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

Ashutosh D. Wechalekar, John Silowsky, Eileen Daniel, Mark Harnett, Michael Spector, Susan B. Sobolov, Candida Cristina Quarta, Michael R. Kurman, Mark Tulchinskiy, Amit Bhattacharyya, Michaela Liedtke
Journal: Blood
Blood (2021) 138 (Supplement 1): 1673.
https://doi.org/10.1182/blood-2021-152488
Published: 2021
Journal Articles

Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Jason Valent, MD, John Silowsky, RN BSN, Michael R. Kurman, MD, Eileen Daniel, Janet Jobes, Mark Harnett, MS, Margaret Ziola, MD, Jessica Roviwong, Sherry Fada, Michael Spector, BS, Susan B. Sobolov, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-139323
Published: 2020
Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Jack Khouri, MD, Faiz Anwer, MD, Christy J. Samaras, DO, Alex V. Mejia Garcia, MD, Omer N. Koc, MD, Beth M. Faiman, PhDCNP, Kimberly Hamilton, CNP, Saveta Mathur, CNP, Cynthia Scott, CNP, Kathleen Stefunek, RN, Josephine Sgobbo, RN, Sherry Fada, Brittany Lewis, Kelly Shepherd, Naqib Ahmad, Madeleine Knebusch, Susan B. Sobolov, PhD, Janet Jobes, Eileen Daniel, Michael Spector, BS, Jason Valent, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21.
https://doi.org/10.1182/blood-2020-137235
Published: 2020